Ascentage Pharma Group International stock
AAPGNASDAQHealthcareISIN US04390B1052
37Score 37 out of 100, Weak
Price and trend
40 / 100
Price history
−54% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 24% below it.
Since December 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 56% below its 52-week high. Largest decline in 2 years: 72% (August 2025 to November 2026).
Chart figures for advanced users
- SMA 50$15.45
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$19.63
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.48
- The lowest closing price of the last twelve months.
- Resistance$34.30
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ascentage Pharma Group International belongs to the Biotechnology industry (China) and, with a market value of $1.4B, is number 156 of 289 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $83.75M (down 43.1% year on year) and a loss of $181.29M.
Show more
- MEQIRI Score 37 out of 100 (Weak): rank 571 of 702 in Healthcare, median 53.
- Our model puts fair value at $28.83, with the price 48% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 114% a year since 2020, Biotechnology median 19.4%.Growth 70
Weaknesses
- High debtDebt 3.7 times equity (latest quarter), Biotechnology median 0.09.Stability 20
- Loss-makingLoss of $217.09M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$209.91M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and growth, while stability and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $19.22 and expensive above $57.65 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.6%. At 10.6% the fair value would be $25.46, at 8.6% it would be $33.26.
Possible value trap: looks cheap, but score below 50, high risk, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 62.1% on the twelve months before. Revenue has grown strongly since 2016, at around 61% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 76%, operating −211%, net −216%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 31 Mar 2027in 138 days
- Last reported
- 18 Aug 2026below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 3.0% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −3.4+54.2%
- Revenue
- $116.43M−1.2%
- Earnings per share
- −3.15−3.0%
- Revenue
- $255.56M−4.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −5.7%Cash runway through 2027 reaffirmed (cash balance of $279.4 million).
“We're pleased to report cash balances were $279.4 million as of June 30, 2026, as well as reaffirming our cash guidance runway through 2027, as we've said before.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 20 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Ascentage Pharma Group International
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- NovavaxNVAX $1.45B42
- Nuvation BioNUVB $1.43B29
- AnaptysBioANAB $1.43B60
- Alto NeuroscienceANRO $1.42B41
- Ocular TherapeutixOCUL $1.38B34
- LB PharmaceuticalsLBRX $1.37B49
- Mineralys TherapeuticsMLYS $1.37B29
- Damora TherapeuticsDMRA $1.36B38
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 23 Jan 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.